BRPI0516302A - rnase t2 humana recombinante e suas utilizações - Google Patents

rnase t2 humana recombinante e suas utilizações

Info

Publication number
BRPI0516302A
BRPI0516302A BRPI0516302-1A BRPI0516302A BRPI0516302A BR PI0516302 A BRPI0516302 A BR PI0516302A BR PI0516302 A BRPI0516302 A BR PI0516302A BR PI0516302 A BRPI0516302 A BR PI0516302A
Authority
BR
Brazil
Prior art keywords
rnase
recombinant human
subject
disclosed
methods
Prior art date
Application number
BRPI0516302-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Levava Roiz
Betty Schwartz
Patricia Smirnoff
Oded Shoseyov
Original Assignee
Yissun Res Dev Company Of The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissun Res Dev Company Of The filed Critical Yissun Res Dev Company Of The
Publication of BRPI0516302A publication Critical patent/BRPI0516302A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
BRPI0516302-1A 2004-09-29 2005-09-28 rnase t2 humana recombinante e suas utilizações BRPI0516302A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61370204P 2004-09-29 2004-09-29
PCT/IL2005/001041 WO2006035439A2 (en) 2004-09-29 2005-09-28 Recombinant human t2 rnase and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0516302A true BRPI0516302A (pt) 2008-09-02

Family

ID=36119279

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516302-1A BRPI0516302A (pt) 2004-09-29 2005-09-28 rnase t2 humana recombinante e suas utilizações

Country Status (9)

Country Link
US (1) US8039240B2 (cg-RX-API-DMAC7.html)
EP (1) EP1805319B1 (cg-RX-API-DMAC7.html)
JP (1) JP5069562B2 (cg-RX-API-DMAC7.html)
AU (1) AU2005288527B9 (cg-RX-API-DMAC7.html)
BR (1) BRPI0516302A (cg-RX-API-DMAC7.html)
CA (1) CA2582041C (cg-RX-API-DMAC7.html)
ES (1) ES2524601T3 (cg-RX-API-DMAC7.html)
WO (1) WO2006035439A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200703313B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE421856T1 (de) * 1999-08-30 2009-02-15 Yissum Res Dev Co Gebrauch einer ribonuclease der t2-familie mit actin-bindender aktivität zur hemmung und/oder der umkehrung von proliferation
US7811981B2 (en) 1999-08-30 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
WO2008016623A2 (en) * 2006-08-01 2008-02-07 Dingee H Clay Iv Improved drying system
EA201100610A1 (ru) * 2008-10-30 2011-10-31 Йиссум Ресёрч Девелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим Лтд. Эффективная экспрессия укороченного человеческого белка rnaset2 в e.coli
WO2011084995A2 (en) * 2010-01-05 2011-07-14 Stratasys, Inc. Support cleaning system
CN105764567B (zh) 2013-09-27 2019-08-09 梅维昂医疗系统股份有限公司 粒子束扫描
US9962560B2 (en) 2013-12-20 2018-05-08 Mevion Medical Systems, Inc. Collimator and energy degrader
US10675487B2 (en) 2013-12-20 2020-06-09 Mevion Medical Systems, Inc. Energy degrader enabling high-speed energy switching
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
US9661736B2 (en) 2014-02-20 2017-05-23 Mevion Medical Systems, Inc. Scanning system for a particle therapy system
US10786689B2 (en) 2015-11-10 2020-09-29 Mevion Medical Systems, Inc. Adaptive aperture
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
WO2018009779A1 (en) 2016-07-08 2018-01-11 Mevion Medical Systems, Inc. Treatment planning
US11103730B2 (en) 2017-02-23 2021-08-31 Mevion Medical Systems, Inc. Automated treatment in particle therapy
WO2019006253A1 (en) 2017-06-30 2019-01-03 Mevion Medical Systems, Inc. CONFIGURABLE COLLIMATOR CONTROLLED BY LINEAR MOTORS
CA3121162A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
US11291861B2 (en) 2019-03-08 2022-04-05 Mevion Medical Systems, Inc. Delivery of radiation by column and generating a treatment plan therefor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) * 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) * 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) * 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) * 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) * 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) * 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) * 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) * 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5786457A (en) * 1989-02-23 1998-07-28 Colorado State University Research Foundation Hormone-nuclease compounds and method for regulating hormone related diseases
US5281521A (en) * 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1998039446A2 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
CA2315617A1 (en) * 1997-12-31 1999-07-08 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US7811981B2 (en) * 1999-08-30 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
ATE421856T1 (de) * 1999-08-30 2009-02-15 Yissum Res Dev Co Gebrauch einer ribonuclease der t2-familie mit actin-bindender aktivität zur hemmung und/oder der umkehrung von proliferation
US7101839B1 (en) * 1999-08-30 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
KR100677108B1 (ko) 2003-06-12 2007-02-01 삼성전자주식회사 정보 저장매체

Also Published As

Publication number Publication date
CA2582041A1 (en) 2006-04-06
US20080131419A1 (en) 2008-06-05
ES2524601T3 (es) 2014-12-10
EP1805319A4 (en) 2009-12-16
AU2005288527B2 (en) 2011-02-03
WO2006035439A2 (en) 2006-04-06
JP2008514224A (ja) 2008-05-08
WO2006035439A3 (en) 2007-06-28
JP5069562B2 (ja) 2012-11-07
HK1100329A1 (en) 2007-09-14
AU2005288527B9 (en) 2011-07-28
EP1805319B1 (en) 2014-09-03
ZA200703313B (en) 2008-09-25
US8039240B2 (en) 2011-10-18
EP1805319A2 (en) 2007-07-11
CA2582041C (en) 2015-08-04
AU2005288527A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
BRPI0516302A (pt) rnase t2 humana recombinante e suas utilizações
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
SG160357A1 (en) Compositions and methods for topical application and transdermal delivery of botulinum toxins
BR112022001359A2 (pt) Método e composição para anticorpos anti-cd73 e variantes
BRPI0814781A8 (pt) ''proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico descarboxilase''
CY1110734T1 (el) Μεθοδος παραγωγης μονιμων ανθρωπινων κυτταρικων σειρων
BRPI0411182A (pt) método para aumentar a toleráncia de uma planta ao estresse abiótico, método para aumentar a biomassa de uma planta, construto de ácido nucléico, polipeptìdio isolado e célula de planta
BR112012016320B8 (pt) Método para tratar material celulósico, polipeptídeo, molécula de ácido nucleico isolada, vetor de expressão recombinante, célula hospedeira, processos para produzir um polipeptídeo, e para obter uma preparação de enzima, preparação de enzima, e, uso do polipeptídeo ou da preparação de enzima
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales
BRPI0915531A2 (pt) Composição de enzima de sacarificação e método de sacarificação da mesma
DK1824970T3 (da) Thricoderma reesei-glycoamylase og homologer heraf
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
IL216703A0 (en) Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
BRPI0819649A2 (pt) método, organismo geneticamente modificado, e, célula de levedura recinbinante
BRPI0517932A8 (pt) Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma
BR112022008201A2 (pt) Degradação de proteínas de superfície usando agente de ligação biespecífico
BR112012033701A2 (pt) polipeptídeo tendo atividade de degradação de carbohidrato e seus usos
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
BR112018006480A2 (pt) ?vetor, método de tratamento de uma doença ou condição, composição, combinação de um vetor, kit, uso de um vetor, método para a modulação in vivo da atividade eletrofisiológica de uma célula
BR112021024819A2 (pt) Acetato quinase engenheirada, composição, sequência de polinucleotídeos, vetor de expressão, célula hospedeira, e, método de produção de uma acetato quinase engenheirada
WO2008041014A3 (en) Interferon- alpha constructs for use in the treatment of diseases characterised by abnormal cell proliferation such as cancer
BR112015029081A2 (pt) Célula hospedeira myceliophthora thermophila expressando uma enzima beta-xilosidase recombinante, enzima beta-xilosidase recombinante expressada por meio da mesma, composição, uso de célula hospedeira, enzima beta-xilosidase ou composição e métodos de produção de açúcares fermentescíveis e de produção de bioproduto a partir de biomassa
WO2008030901A3 (en) Biomarker fragments for the detection of human bnp
WO2007130575A3 (en) Protection against oxidative damage in cells

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements